Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?

Clinical Therapeutics

Volumn 37, Issue 12, 2015, Pages 2716-2731

  Barter, Philip J ^a   Rye, Kerry Anne ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

atherosclerosis; CETP inhibition; HDL raising; reconstituted HDL infusion

Indexed keywords

ABC TRANSPORTER A1; ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TORCETRAPIB; AGENTS AFFECTING LIPID METABOLISM;

ANGIOCARDIOGRAPHY; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES CONTROL; DRUG SAFETY; HUMAN; INNATE IMMUNITY; INSULIN SENSITIVITY; NONHUMAN; REVIEW; CARDIOVASCULAR DISEASE;

CARDIOVASCULAR DISEASES; HUMANS; LIPID REGULATING AGENTS; LIPOPROTEINS, HDL;

EID: 84951907122     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.07.021     Document Type: Review

References (86)

1. Emerging Risk Factors Collaboration E. Di Angelantonio, N. Sarwar, P. Perry, and et al. Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
2. P Barter, AM Gotto, JC LaRosa, and et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
3. JJ Badimon, L Badimon, and V. Fuster Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 85 1990 1234 1241
4. N Duverger, H Kruth, F Emmanuel, and et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits Circulation 94 1996 713 717
5. AS Plump, CJ Scott, and JL. Breslow Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse Proc Natl Acad Sci U S A 91 1994 9607 9611
6. EM Rubin, RM Krauss, EA Spangler, and et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI Nature 353 1991 265 267
7. KA Rye, CA Bursill, G Lambert, and et al. The metabolism and anti-atherogenic properties of HDL J Lipid Res Suppl:S195-200 2009 50
8. KA Rye, and PJ. Barter Cardioprotective functions of HDLs J Lipid Res 55 2014 168 179
9. A Rohatgi, A Khera, JD Berry, and et al. HDL cholesterol efflux capacity and incident cardiovascular events N Engl J Med 371 2014 2383 2393
10. D Saleheen, R Scott, S Javad, and et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study Lancet Diabetes Endocrinol 3 2015 507 513
11. M Riwanto, and U. Landmesser High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease J Lipid Res 54 2013 3227 3243
12. Cholesterol Treatment Trialists Collaboration C Baigent, L Blackwell, J Emberson, and et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
13. PJ Barter, G Brandrup-Wognsen, MK Palmer, and SJ. Nicholls Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database J Lipid Res 51 2010 1546 1553
14. SJ Nicholls, EM Tuzcu, I Sipahi, and et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 2007 499 508
15. PJ Barter, and KA. Rye Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 28 2008 39 46
16. MH Frick, O Elo, K Haapa, and et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
17. V Manninen, L Tenkanen, P Koskinen, and et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment Circulation 85 1992 37 45
18. HB Rubins, SJ Robins, D Collins, and et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418
19. Bezafibrate Infarction Prevention (BIP) study Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease Circulation 102 2000 21 27
20. A Tenenbaum, M Motro, EZ Fisman, and et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome Arch Intern Med 165 2005 1154 1160
21. A Keech, RJ Simes, P Barter FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
22. R Scott, R O'Brien, G Fulcher, et al. Event Lowering in Diabetes Study (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 2009 493 498
23. AS Group, HN Ginsberg, MB Elam, and et al. Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
24. HN. Ginsberg The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses Diabetes Care 34 Suppl 2 2011 S107 S108
25. ET Bodor, and S. Offermanns Nicotinic acid: an old drug with a promising future Br J Pharmacol 153 Suppl 1 2008 S68 S75
26. PL Canner, KG Berge, NK Wenger, and et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
27. AJ Taylor, TC Villines, EJ Stanek, and et al. Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
28. AIM-HIGH Investigators WE Boden, JL Probstfield, T Anderson, and et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
29. HPS2-THRIVE Collaborative Group MJ Landray, R Haynes, JC Hopewell, and et al. Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
30. SE Nissen, T Tsunoda, EM Tuzcu, and et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
31. JC Tardif, J Gregoire, PL L'Allier, and et al. Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 2007 1675 1682
32. A Gille, R Easton, D D'Andrea, and et al. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects Arterioscler Thromb Vasc Biol 34 2014 2106 2114
33. C Tardy, M Goffinet, N Boubekeur, and et al. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice Atherosclerosis 232 2014 110 118
34. RS Kootte, LP Smits, FM van der Valk, and et al. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA J Lipid Res 56 2015 703 712
35. GK Hovingh, LP Smits, C Stefanutti, and et al. The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study Am Heart J 169 736-742 2015 e1
36. JC Tardif, CM Ballantyne, P Barter Can HDL Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial Eur Heart J 35 2014 3277 3286
37. FM Sacks, LL Rudel, A Conner, and et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo J Lipid Res 50 2009 894 907
38. R Waksman, R Torguson, KM Kent, and et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
39. PJ Barter, and KA. Rye Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk J Lipid Res 53 2012 1755 1766
40. YC Ha, and PJ. Barter Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species Comp Biochem Physiol B Comp Biochem 71 1982 265 269
41. M Sugano, N Makino, S Sawada, and et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits J Biol Chem 273 1998 5033 5036
42. CW Rittershaus, DP Miller, LJ Thomas, and et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis Arterioscler Thromb Vasc Biol 20 2000 2106 2112
43. YW Liaw, CY Lin, YS Lai, and et al. A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit PLoS One 9 2014 e111529
44. H Okamoto, F Yonemori, K Wakitani, and et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 2000 203 207
45. LA Morehouse, ED Sugarman, PA Bourassa, and et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits J Lipid Res 48 2007 1263 1272
46. KR Marotti, CK Castle, TP Boyle, and et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein Nature 364 1993 73 75
47. AS Plump, L Masucci-Magoulas, C Bruce, and et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression Arterioscler Thromb Vasc Biol 19 1999 1105 1110
48. M Westerterp, CC van der Hoogt, W de Haan, and et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE∗3-Leiden mice Arterioscler Thromb Vasc Biol 26 2006 2552 2559
49. VL Herrera, SC Makrides, HX Xie, and et al. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein Nat Med 5 1999 1383 1389
50. RB Hildebrand, B Lammers, I Meurs, and et al. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency Arterioscler Thromb Vasc Biol 30 2010 1439 1445
51. PS MacLean, JF Bower, S Vadlamudi, and et al. Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice Arterioscler Thromb Vasc Biol 23 2003 1412 1415
52. B Foger, M Chase, MJ Amar, and et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice J Biol Chem 274 1999 36912 36920
53. PM Cazita, JA Berti, C Aoki, and et al. Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice J Lipid Res 44 2003 33 40
54. AC Casquero, JA Berti, AG Salerno, and et al. Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice J Lipid Res 47 2006 1526 1534
55. T Hayek, L Masucci-Magoulas, X Jiang, and et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene J Clin Invest 96 1995 2071 2074
56. A Thompson, E Di Angelantonio, N Sarwar, and et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk JAMA 299 2008 2777 2788
57. BF Voight, GM Peloso, M Orho-Melander, and et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
58. W Niu, and Y. Qi Circulating cholesteryl ester transfer protein and coronary heart disease: mendelian randomization meta-analysis Circ Cardiovasc Genet 8 2015 114 121
59. PM Ridker, G Pare, AN Parker, and et al. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study Circ Cardiovasc Genet 2 2009 26 33
60. TH Johannsen, R Frikke-Schmidt, J Schou, and et al. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects J Am Coll Cardiol 60 2012 2041 2048
61. PJ Barter, M Caulfield, M Eriksson ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
62. ML Bots, FL Visseren, GW Evans RADIANCE 2 Investigators Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 2007 153 160
63. JJ Kastelein, SI van Leuven, L Burgess RADIANCE 1 Investigators Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 2007 1620 1630
64. SE Nissen, JC Tardif, SJ Nicholls ILLUSTRATE Investigators Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 2007 1304 1316
65. RG Clerc, A Stauffer, F Weibel, and et al. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels J Hypertens 28 2010 1676 1686
66. X Hu, JD Dietz, C Xia, and et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition Endocrinology 150 2009 2211 2219
67. B Simic, M Hermann, SG Shaw, and et al. Torcetrapib impairs endothelial function in hypertension Eur Heart J 33 2012 1615 1624
68. PJ Barter, KA Rye, JC Tardif, and et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial Circulation 124 2011 555 562
69. JA Kuivenhoven, GJ de Grooth, H Kawamura, and et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia Am J Cardiol 95 2005 1085 1088
70. GG Schwartz, AG Olsson, M Abt dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
71. C Besler, K Heinrich, L Rohrer, and et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J Clin Invest 121 2011 2693 2708
72. CP Cannon, S Shah, HM Dansky, and et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
73. JJ Kastelein, J Besseling, S Shah, and et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study Lancet 385 2015 2153 2161
74. MJ Forrest, D Bloomfield, RJ Briscoe, and et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br J Pharmacol 154 2008 1465 1473
75. AM Gotto Jr., U Kher, MS Chatterjee DEFINE Investigators Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study J Cardiovasc Pharmacol Ther 19 2014 543 549
76. SJ Nicholls, HB Brewer, JJ Kastelein, and et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial Jama 306 2011 2099 2109
77. JG Suico, MD Wang, S Friedrich, and et al. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults J Pharm Pharmacol 66 2014 1576 1585
78. T Teramoto, M Takeuchi, Y Morisaki, and et al. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia Am J Cardiol 113 2014 2021 2029
79. G Cao, TP Beyer, Y Zhang, and et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure J Lipid Res 52 2011 2169 2176
80. DS Small, AB Ke, SD Hall, and et al. Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches J Clin Pharmacol 55 2015 757 767
81. GK Hovingh, JJ Kastelein, SJ van Deventer, and et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial Lancet 2015 [Epub ahead of print]
82. L Yvan-Charvet, F Matsuura, N Wang, and et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL Arterioscler Thromb Vasc Biol 27 2007 1132 1138
83. L Yvan-Charvet, J Kling, T Pagler, and et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib Arterioscler Thromb Vasc Biol 30 2010 1430 1438
84. DJ Rader, and et al. Circulation 130 2014 A122252
85. P. Barter Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial Am J Cardiol 104 2009 10E 15EE
86. SJ Nicholls, EM Tuzcu, DM Brennan, and et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation 118 2008 2506 2514